Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral...

Area of Science:

• Neuroscience
• Pharmacology
• Pain Research

Background:

• Endocannabinoids anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) are key players in pain modulation.
• AEA is primarily hydrolyzed by fatty-acid amide hydrolase (FAAH), and 2-AG by monoacylglycerol lipase (MGL).
• Inhibitors like URB597 (FAAH inhibitor) and URB602 (MGL inhibitor) are being investigated for therapeutic potential.

Purpose of the Study:

• To elucidate the precise roles of cannabinoid CB₁ and CB₂ receptors in the peripheral antinociceptive effects of AEA, 2-AG, URB597, and URB602.
• To investigate the underlying mechanisms of these endocannabinoids and their enzyme inhibitors in a mouse model of neuropathic pain.

Main Methods:

• Evaluated mechanical allodynia and thermal hyperalgesia in 436 male C57BL/6, cnr1KO, and cnr2KO mice.
• Utilized pharmacological tools, including cannabinoid CB₁ (AM251) and CB₂ (AM630) receptor antagonists.
• Administered peripheral subcutaneous injections of AEA, 2-AG, WIN55,212-2 (WIN), URB597, and URB602.

Main Results:

• AEA, 2-AG, WIN, URB597, and URB602 all significantly reduced mechanical allodynia and thermal hyperalgesia.
• Antinociceptive effects of 2-AG, WIN, and URB602 were blocked by both AM251 and AM630; AEA and URB597 effects were blocked only by AM251.
• Antinociceptive effects of AEA and URB597 were present in cnr2KO mice but absent in cnr1KO mice, indicating CB₁ receptor mediation.
• Antinociceptive effects of 2-AG, WIN, and URB602 were altered in both cnr1KO and cnr2KO mice, suggesting involvement of both CB₁ and CB₂ receptors.

Conclusions:

• The antinociceptive properties of AEA and URB597 are primarily mediated by CB₁ receptors.
• The anti-hyperalgesic effects of 2-AG and URB602 require both CB₁ and CB₂ receptors, while their anti-allodynic actions are CB₂-dependent.
• These findings clarify the distinct roles of CB₁ and CB₂ receptors in mediating the pain-relieving effects of endocannabinoids and their inhibitors.